Olema Pharmaceuticals (OLMA) Cash from Financing Activities (2020 - 2026)

Olema Pharmaceuticals (OLMA) has reported Cash from Financing Activities for 7 consecutive years, with $45.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 20487.39% year-over-year to $45.7 million; the TTM figure through Mar 2026 stood at $256.8 million (down 1.32% YoY), while the FY2025 annual figure was $211.3 million, down 21.4% from the prior year.
• Cash from Financing Activities retreated to $45.7 million in Q1 2026 per OLMA's latest filing, from $213.6 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $244.3 million in Q4 2024 and bottomed at -$2.5 million in Q2 2025.
• Historically, Cash from Financing Activities has averaged $38.8 million across 5 years, with a median of $273000.0 in 2022.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 123134.91% — and 2025, when it sank 116.14%.
• Olema Pharmaceuticals' Cash from Financing Activities stood at $273000.0 in 2022, then jumped by 91.58% to $523000.0 in 2023, then soared by 46611.28% to $244.3 million in 2024, then decreased by 12.59% to $213.6 million in 2025, then sank by 78.6% to $45.7 million in 2026.
• Business Quant data shows OLMA's Cash from Financing Activities at $45.7 million in Q1 2026, $213.6 million in Q4 2025, and $41000.0 in Q3 2025.